Ascend Capital’s AMAG Pharmaceuticals AMAG Stock Holding History

Ascend Capital’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-165,476	Closed	-$3.04M	–	209
2017 Q2	$3.04M	Buy	+165,476	New	+$3.28M	0.14%	123

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ascend Capital's AMAG Position: Q3 2017 in Review

Ascend Capital sold out of AMAG Pharmaceuticals (AMAG) in Q3 2017, closing a stake of 165,476 shares — an estimated $3.04M sold.

Ascend Capital first reported a position in AMAG in Q2 2017 and held it in 1 quarter. The position peaked at $3.04M in Q2 2017. 187 funds tracked by Wall St. Rank hold AMAG as of Q3 2017.

Ascend Capital reported no remaining AMAG Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Ascend Capital sold 165,476 AMAG Pharmaceuticals shares in Q3 2017, an estimated $3.04M.
Ascend Capital first reported a position in AMAG Pharmaceuticals in Q2 2017 and held it in 1 quarter.
Ascend Capital's AMAG Pharmaceuticals position peaked at $3.04M in Q2 2017.
187 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q3 2017.

Based on Ascend Capital's 13F filing for Q3 2017, filed 13 Nov 2017.